YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* BioRestorative Therapies (BRTX [https://seekingalpha.com/symbol/BRTX]) said [https://seekingalpha.com/pr/20639163-biorestorative-therapies-announces-reverse-stock-split] on Wednesday that it will effect a 1-for-20 reverse stock split at…
MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (Nasdaq: BRTX) ("BioRestorative" or the "Company"), a late-stage clinical regenerative medicine company, today announced that the Company's Board of Director…
Alvotech (ALVO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.14 per share a year ago. These figures are adjusted for non-recurring items. This qua…
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.48 per share a year ago. These figures are adjusted for non-recurri…
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, suggesting potential breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. In the Green - Premarket…
(RTTNews) - Shares of BioRestorative Therapies, Inc. (BRTX) are up 56% in pre-market trading after Kaos Capital announced it has acquired a 4.9% stake in the company and is seeking immediate engagement with the board to explore strategic o…
(RTTNews) - BioRestorative Therapies Inc. (BRTX), a late-stage clinical regenerative medicine company, on Tuesday announced completion of Phase 2 dosing for BRTX-100 in the treatment of chronic lumbar disc disease (cLDD). Shares rose by 20…
Healthcare stocks were lower Tuesday afternoon, with the NYSE Healthcare Index shedding 0.6% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
PTC Therapeutics (PTCT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to earnings of $10.04 per share a year ago. These figures are adjusted for non-recurring items.…
(RTTNews) - BioRestorative Therapies, Inc. (BRTX) has entered a strategic partnership with globally recognized dermatologist Dr. David J. Goldberg, aiming to accelerate clinical validation and broaden adoption of its regenerative BioCosmec…
New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company’s proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th at the 2026 Orthopaedic Research Socie…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Elong Power Holding Ltd. 286,995,635 0.0734 0.0576 0.0587 +0.0107 BioResto…
(RTTNews) - Shares of BioRestorative Therapies Inc. (BRTX) are up by 30% as the company participates in the Be+Well Beauty and Wellness Show in New York City, held March 8-10, 2026. The company is planning to present its BioCosmeceutical p…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Blue Hat Interac.Entert.Techn. 199,973,207 0.0781 0.066 0.071 +0.0052 Reli…
GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. BioRestorative believes its cell-based therapeutic candidates may offer the potential f…
MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and prod…
MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and prod…
BioRestorative completed a Type B meeting with the U.S. Food and Drug Administration (“FDA”) regarding a potential accelerated Biologics License Application (“BLA”) approval pathway for the Fast-Track-Designated BRTX-100 program for the tr…
(RTTNews) - Healthcare and biotechnology stocks saw notable moves in after-hours trading on Monday, with several companies posting strong gains despite limited news flow. Novo Nordisk A/S (NVO) surged in extended trading, climbing 9.48% to…
(RTTNews) - Several small-cap biotech and therapeutics companies posted notable gains in Monday's after-hours trading session, driven by earnings updates, financial guidance, and regulatory developments. Inotiv, Inc. (NOTV) surged 36.61% i…
MELVILLE, N.Y., Nov. 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announce…
Image source: The Motley Fool. Date Wednesday, Nov. 12, 2025 at 4:30 p.m. ET Call participants Chief Executive Officer — Lance Alstodt Chief Financial Officer — Robert Eugene Kristal Chief Scientific Officer — Francisco J. Silva Need a quo…
Earnings Call Insights: BioRestorative Therapies, Inc. (BRTX) Q3 2025 MANAGEMENT VIEW * Lance Alstodt, Chairman of the Board, President & CEO, emphasized, "we continue to execute well across all areas of our business in the third quarter.…
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.01 per share a year ago. These figures are adjusted for non-recurring ite…
(RTTNews) - Several biotechnology and pharmaceutical stocks showed notable price increases during Friday's after-hours trading session, with movement driven by upcoming data releases, recent earnings reports, and prior corporate updates. I…
MELVILLE, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announce…
MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announce…
MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announce…
MELVILLE, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Bayer Aktiengesellschaft (BAYRY) is a stock that can certainly grab the attention of many investors, but do its recent retu…
MELVILLE, N.Y., Oct. 07, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today is pleas…
MELVILLE, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced it has entered into…
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Adaptive Biotechnologies (ADPT) been one of those stocks this year? By taking a look at the stock's…
Investing.com - BioRestorative Therapies (NASDAQ: BRTX) reported second quarter EPS of $-0.300, $0.08 better than the analyst estimate of $-0.380. Revenue for the quarter came in at $303K versus the consensus estimate of $340K. BioRestorat…
* BioRestorative Therapies press release [https://seekingalpha.com/pr/20198632-biorestorative-therapies-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:BRTX [https://seekingalpha.com/symbol/BRTX]): Q2 GAAP EPS…
MELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products,…